Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet A Dunn

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|November 6, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysisPaola Cocco, Chris Bojke, Claire Hulme, et al.
The British Journal of Radiology|September 28, 2019
Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI?: a single centre data-interpretation studyLyn I Jones, Rebecca Geach, Sam A Harding, et al.
British Journal of Haematology|August 16, 2005
Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survivalRichard Lovell, Janet A Dunn, Gulnaz Begum, et al.
British Journal of Haematology|November 26, 2013
Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497)Elizabeth Molyneux, Blair Merrick, Farhat L Khanim, et al.
BMC Cancer|October 25, 2006
A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancerAngela V Ryan, Sue Wilson, Michael J O Wakelam, et al.
BMC Cancer|April 7, 2018
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsLouise Hiller, Janet A Dunn, Shrushma Loi, et al.
Health and Quality of Life Outcomes|July 2, 2025
Quality of life and patient reported outcomes in the UK Mammo-50 randomised trial of annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and overAndrea Marshall, Peter Donnelly, Nada Elbeltagi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working PartyBradley M Augustson, Gulnaz Begum, Janet A Dunn, et al.
European Urology Focus|July 21, 2017
A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder CancerRichard T Bryan, Tim Evans, Janet A Dunn, et al.
BMC Cancer|November 2, 2006
Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care populationSue Wilson, Michael J O Wakelam, Richard F D Hobbs, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|November 6, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysisPaola Cocco, Chris Bojke, Claire Hulme, et al.
The British Journal of Radiology|September 28, 2019
Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI?: a single centre data-interpretation studyLyn I Jones, Rebecca Geach, Sam A Harding, et al.
British Journal of Haematology|August 16, 2005
Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survivalRichard Lovell, Janet A Dunn, Gulnaz Begum, et al.
British Journal of Haematology|November 26, 2013
Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497)Elizabeth Molyneux, Blair Merrick, Farhat L Khanim, et al.
BMC Cancer|October 25, 2006
A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancerAngela V Ryan, Sue Wilson, Michael J O Wakelam, et al.
BMC Cancer|April 7, 2018
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint resultsLouise Hiller, Janet A Dunn, Shrushma Loi, et al.
Health and Quality of Life Outcomes|July 2, 2025
Quality of life and patient reported outcomes in the UK Mammo-50 randomised trial of annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and overAndrea Marshall, Peter Donnelly, Nada Elbeltagi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working PartyBradley M Augustson, Gulnaz Begum, Janet A Dunn, et al.
European Urology Focus|July 21, 2017
A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder CancerRichard T Bryan, Tim Evans, Janet A Dunn, et al.
BMC Cancer|November 2, 2006
Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care populationSue Wilson, Michael J O Wakelam, Richard F D Hobbs, et al.
Pageof 6